May 31-June 03, 2024, Valencia, Spain

European Academy of Allergy and Clinical Immunology (EAACI)

June 13−16, 2025, Glasgow, United Kingdom

European Academy of Allergy and Clinical Immunology (EAACI)

Oral icon

Long-term efficacy and safety of remibrutinib in patients with chronic spontaneous urticaria in the Phase 3 REMIX-1 and REMIX-2 studies

M. Metz, A.M. Giménez-Arnau, M. Hide, V. Jain, A. Khemis, M. Lebwohl, M. Palumbo, S. Saini,
E. Şavk, G. Sussman, R. Szalewski, I. Walecka Herniczek, H. Windom, S. Haemmerle, K. Lheritier, Paula G.P. Machado, E-D. Martzloff, N. Seko, P. Wang, A. Zharkov, M. Maurer
Abstract Oral presentation
Oral icon

Effect of remibrutinib on disease activity in patients with chronic spontaneous urticaria: post hoc analysis of Phase 3 REMIX-1 and REMIX-2 studies

M. Maurer, F. Berard, E. Savk, M. Hide, I.A. Neves, K. Lheritier, N. Chapman-Rothe, S. Haemmerle, A.M. Giménez-Arnau
Abstract Oral presentation
Oral icon

Effect of remibrutinib on sleep and daily activities in patients with chronic spontaneous urticaria: Results from the Phase 3 studies

A.M. Giménez-Arnau, M. Hide, M.Lebwohl, G. Sussman, S. Saini, S. Haemmerle, N. Seko, P. Wang, E-D. Martzloff, M. Maurer
Abstract Oral presentation
Oral icon

Safety of remibrutinib in patients with chronic spontaneous urticaria: Results from the Phase 3 REMIX-1 and REMIX-2 studies​

P. Staubach, S. Saini, A.M. Giménez-Arnau, M. Hide, M. Lebwohl, G. Sussman, S. Haemmerle,
K. Lheritier, E-D. Martzloff, A. Zharkov, M. Maurer
Abstract Poster
Oral icon

Physicians’ prescribing patterns and perceptions of treatments for chronic spontaneous urticaria: Real world data from Urticaria Voices​ study

J.A. Bernstein, K. Weller, M-M.Balp, J. McCarthy, P. Laires, P. Saraswat, T. Raftery, T.A. Winders
Abstract Flash Talk
Oral icon

Worldwide experiences and unmet needs of patients with chronic spontaneous urticaria and treating physicians: The Urticaria Voices study​

T.A. Winders, J.A. Bernstein, M-M. Balp, J. McCarthy, P. Laires, P. Saraswat, T. Raftery, K. Weller
Abstract Flash Talk
Poster icon

Remibrutinib improves chronic spontaneous urticaria independent of baseline immunoglobulin E levels in the phase 3 REMIX studies

J. Reed, M. Lebwohl, V. Jain, H. Windom, X. Jiang, N. Seko, P. Wang, S. Haemmerle, A.G-Arnau
Abstract Oral Presentation
Poster icon

Remibrutinib demonstrates sustained control of angioedema in patients with chronic spontaneous urticaria: 52-week treatment results from the phase 3 REMIX studies

M. Hide, P. Staubach, A. Khemis, V. Jain, W. Huiping, S. Gogate, E.D. Martzloff, S. Haemmerle, C.E. Ortmann, N.C-Rothe, M. Lebwohl
Abstract Oral Presentation
Poster icon

The Urticaria Voices study: Experiences and unmet needs of patients with chronic inducible urticaria (CIndU)

J.A. Bernstein, T.A. Winders, J. McCarthy, P. Saraswat, N.C-Rothe, T. Raftery, K. Weller
Abstract Oral Presentation
Poster icon

Impact of chronic inducible urticaria (CIndU) on patients’ health-related quality of life: Results from Urticaria Voices study

T.A. Winders, J.A. Bernstein, J. McCarthy, P. Saraswat, N.C-Rothe, T. Raftery, K. Weller
Abstract Oral Presentation
Poster icon

Knowledge, attitudes and practice patterns in chronic spontaneous urticaria management among Italian General Practitioners: Baseline data from the BRIDGE implementation science study

R. Asero, E. Iemoli, N.C-Rothe, P. Saraswat, V. Nallasamy, A. Herbst, B. Gaglio, F. Speranza, O. Bonavita, T. Raftery, P. C. Pinton
Abstract Oral Presentation
Poster icon

Evaluation of real-world mental health and sleep outcomes over time in US patients with chronic spontaneous urticaria

M.A. Riedl, D. Patil, M. Kuruvilla, J. Doran, I. Pivneva, F. Kinkead, P. Orfanos, T. Raftery, G. Yosipovitch
Abstract Oral Presentation
Novartis logo
Cookie Settings
© Copyright 2025 Novartis Pharma AG